久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > Pulmatrix
Pulmatrix
Pulmatrix Pulmatrix

美國Pulmatrix  
Pulmatrix公司,一個臨床階段的生物制藥公司,開發用于治療,預防和傳輸控制的傳染病和進步呼吸系統疾病的吸入療法。它提供吸入呼吸道襯調制陽離子藥物,刺激呼吸道內的宿主防御機制來治療和預防流感,鼻病毒,慢性肺疾病。該公司成立于2003年,總部設在美國馬薩諸塞州列克星敦。

Pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. The platform, called iSPERSE (inhaled small particles easily respirable and dispersible), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. The iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance including our novel iCALM (inhaled Cationic Airway Lining Modulators) therapies, small molecules, biologics, and multi-drug combinations.

With the iSPERSE platform, Pulmatrix is developing a broad pipeline to prevent and treat a range of respiratory diseases with significant unmet medical needs including chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis, and severe asthma. The company has demonstrated comprehensive data showing that iSPERSE can be applied to a broad range of therapeutic compounds ranging from small molecules to proteins and including our lead dry powder iCALM therapies. Further optimization of select iSPERSE therapeutic formulations across a range of drug loads for scale up, manufacturing conditions, and stability testing has yielded promising results for the potential of the platform. Potential advantages of iSPERSE platform therapeutics on clinical treatment efficacy include reduced total inhaled powder mass, enhanced dosing efficiency, reduced cost of goods and improved safety and tolerability profiles.

Proprietary iCALM therapies comprise combinations of cationic salts designed to trigger multiple mechanisms that harness the body’s natural host defense and immune response in the airway to reduce inflammation, safely prevent and treat respiratory infections, and prevent acute exacerbations in patients with chronic inflammatory airway disease. The company’s lead dry powder iCALM drug candidate is the first clinical candidate based upon the iSPERSE platform. A host-targeted therapy, iCALM is designed to have broad application for respiratory diseases such as COPD, asthma, and cystic fibrosis and respiratory infections including influenza, influenza-like illness (ILI), rhinovirus, ventilator associated pneumonia (VAP) and respiratory syncytial virus (RSV). Pulmatrix has successfully completed Phase 1 safety and tolerability testing of our lead dry powder iCALM drug candidate in human studies including allergic asthmatics and COPD patients. The company has active clinical programs in COPD and cystic fibrosis.

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 亚洲一区二区三区91 | 综合网天天 | 亚洲专区路线一路线二天美 | 三男一女的伦交动态图 | 国产精品一区二区久久不卡 | 黄色一级视频免费观看 | 亚洲欧美专区 | 免费观看亚洲视频 | 国产亚洲午夜精品a一区二区 | 欧美日本道免费二区三区 | 欧美天天 | 精品国产欧美一区二区五十路 | 精品国产一区二区二三区在线观看 | 国产精品一区二区免费 | 国产一级自拍 | 青青草国产在线视频 | 福利视频一区二区牛牛 | 日韩精品欧美高清区 | 国产在线视频专区 | 欧美一区二区免费 | 亚洲精品在线免费观看视频 | 亚洲国产成人精品区 | 欧美在线视频网站 | 在线免费黄色网址 | 中文字幕一区二区三区久久网站 | a黄网站 | 日韩在线视频观看 | 国产精品福利久久久久久小说 | 91亚洲国产成人久久精品网址 | 亚洲日本一区二区三区高清在线 | 欧美爱爱动态图 | 久久亚洲精品国产精品777777 | 国产日韩视频一区 | 九九精品99久久久香蕉 | 日韩经典第一页 | 欧美交配| 国产日韩欧美在线观看不卡 | 欧美日韩一区二区三区久久 | 九九久久亚洲综合久久久 | 99久久国产亚洲综合精品 | 中文字幕一区久久久久 |